Clinical trials with the EGFR TKI gefitinib in breast cancer have shown limited clinical responses and a low disease control rate, particularly in triple-negative breast cancer, despite the higher degree of EGFR overexpression in this subtype [64, 99, 100]. Here, EGFR is linked to triple-negative breast carcinoma.